---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-070948"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:43:33.808273+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tivic Health enters $4.1M GMP manufacturing agreement with Scorpius for Entolimod ARS

## Summary
- Scorpius BioManufacturing to perform GMP validation for Entolimod, a TLR5 agonist for Acute Radiation Syndrome (ARS).
- Total estimated investment ~$4.1M comprising ~$2.4M service fees and pass-through costs for consumables, external services.
- Scorpius to perform cell line verification, GMP scale-up, fill/finish, analytical development, process optimization.
- Purpose is to prepare complete CMC package for FDA BLA submission for Entolimod.
- Manufacturing at Scorpius' San Antonio, TX facility; aims for leaner supply chain.

## SEC filing metadata
- accession: 0000950170-25-070948
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017025070948/0000950170-25-070948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017025070948/tivc-20250509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-070948
- JSON: https://secwatch.observer/filing/0000950170-25-070948.json
- Plain text: https://secwatch.observer/filing/0000950170-25-070948.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.